ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

TITLE:

USE OF PRAVASTATIN FOR PREVENTION AND TREATMENT OF PREECLAMPSIA IN HIGH RISK PREGNANCIES IN PAKISTANI WOMEN: RANDOMIZED CONTROLLED TRIAL STUDY

AUTHORS:

Dr Noureen Kauser, Dr Noor-ul-huda, Dr. Ali Hadi

ABSTRACT:

Objective: To compare the effects of pravastatin and control group for prevention of Preeclampsia in high risk pregnancies in Pakistani women. Design: double-blind randomization, placebo-controlled trial Patient(s): The study comprised a total of 400 singleton pregnant women with high risk of preeclampsia Intervention(s): Pravastatin was given once daily for 4 weeks starting from the 13th week to the 16th week of gestation. Main Outcome Measure(s): incidence of preeclampsia Result(s): 16 cases developed preeclampsia in the control group (11 cases were severe and the remaining 5 were mild) with a percentage of 8% instead of 6 cases in the study group (4 cases were severe and 2 were mild) with a percentage of 3%. Conclusion: Pravastatin can be used as an effective agent in the prevention and treatment of preeclampsia in pregnant women. Key words: pravastatin, placebo, pregnancy, preterm preeclampsia.

FULL TEXT

Top
  • Follows us on
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.